Imminent FDA Approval Means Now Is the Perfect Time to Own this Biotech Stock

I love investing in biotech stocks because they have single handedly propelled my model portfolio to massive outperformance over the years.

Biogen (NASDAQ: BIIB), Regeneron Pharmaceuticals (NASDAQ: REGN), and Gilead Sciences (NASDAQ: GILD) have been some of my biggest winners over the past decade.

But now with market caps of $43 billion, $60 billion, and $80 billion, respectively, Wall Street has caught on and limited the potential future returns by bidding up their stock prices.

So, allow me to specify… I love investing in unknown small-to-medium-sized biotech companies because they give you the best opportunity to significantly outperform any market cycle.

See, they’re not necessarily correlated with the broader market because investors value these stocks on their underlying fundamentals i.e. their ability to create new drugs that solve massive human health problems with FDA approval.

Take a look at my biggest biotech winner this year: Novavax, Inc. (NASDAQ: NVAX).

While the broader market was faltering due to the unknown effects coronavirus would have on the economy back in March, NVAX used this as an opportunity to work on a vaccine that could end the pandemic.

The stock surged from about $7 per share in March all the way to $190 by August for a 2,614% return for investors who timed it perfectly.

Now, I wasn’t able do that unfortunately (practically nobody can). But I’ll take the 527% return I did generate in just about three months.

The single most important factor to consider when investing in biotech companies is timing – when to get in and when to get out.

To do that, you have the analyze the likelihood that the biotech’s newest drug will be successful and earn FDA approval in the quickest time possible.

And I think I found just the pick.

It’s a medium sized biotech company worth about $7 billion today.

Here it is…

My No. 1 Biotech Stock to Own Today

Like I said before, timing is everything when it comes to picking the best biotech stock.

And I really think the timing is perfect right now for one mid-sized biotech company – Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) – to deliver investors 1,000% returns.

finviz dynamic chart for  ACAD

Here’s a brief summary of what you need to know about the company now…

Acadia develops and commercializes biopharmaceutical products to address central nervous system disorders.

The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia.

It already has one drug approved by the FDA that helped it generate $339 million last year.

And it has another drug in the pipeline now that’s expected to pass soon and help the company generate $2.5 billion by 2024.

Where I first discovered this stock…

I was perusing some of my favorite finance sites, and I happened upon this video, where Legendary Analyst, Matt McCall predicted his #1 Stock of 2020.

Here's what he had to say about it:

“I'm confident that this is my next big winner — and I haven't felt this way since back in 2009. This company is on the cutting-edge of one of the greatest medical breakthroughs of the 21st century. You can't afford to ignore this.”

Before you take any action, please watch McCall's latest prediction.

$3 EV Play No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$2 Biotech Stock

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only $2.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works